TABLE 1.
Mean Patient Time (in Hours) for 16-Week Treatment (standard errors in parentheses)
| Treatment Arm |
N | Total Patient Time*** |
Total Time in Assessmentsa*** |
Total Time in MM/CBI Sessions |
Total Time in Self-Help Meetings |
Total Travel Timeb*** |
|
|---|---|---|---|---|---|---|---|
| MM | CBI | ||||||
| MM + placebo | 153 | 30.34 (2.60) |
4.47 (0.02) |
3.14 (0.08) |
--- | 8.07 (1.75) |
14.65 (1.12) |
| MM + naltrexone | 154 | 32.60 (3.31) |
4.44 (0.02) |
3.06 (0.10) |
--- | 10.72 (2.25) |
14.39 (1.22) |
| MM + naltrexone + acamprosate | 148 | 31.30 (3.02) |
4.42 (0.02) |
3.00 (0.09) |
--- | 9.31 (1.85) |
14.56 (1.31) |
| CBI only | 155 | 34.85 (3.05) |
3.91 (0.01) |
--- | 8.69 (0.36) |
5.97 (1.71) |
16.28 (1.52) |
| MM + acamprosate | 151 | 33.73 (4.29) |
4.43 (0.02) |
3.07 (0.09) |
--- | 9.38 (2.30) |
16.84 (2.44) |
| MM + placebo + CBI | 156 | 44.64 (2.52) |
4.65 (0.03) |
3.09 (0.08) |
9.02 (0.33) |
7.41 (1.44) |
20.46 (1.36) |
| MM + naltrexone + CBI | 154 | 44.88 (2.82) |
4.65 (0.02) |
3.10 (0.08) |
8.90 (0.30) |
9.15 (1.82) |
19.08 (1.13) |
| MM + naltrexone + acamprosate + CBI | 157 | 43.07 (2.96) |
4.57 (0.03) |
2.90 (0.09) |
8.18 (0.35) |
9.06 (1.84) |
18.35 (1.42) |
| MM + acamprosate + CBI | 151 | 46.38 (3.60) |
4.63 (0.03) |
3.06 (0.09) |
8.56 (0.35) |
9.30 (1.79) |
20.82 (2.07) |
| All Treatmentsc | 1,379 | 38.02 (1.08) |
4.47 (0.01) |
3.05 (0.03) |
8.67 (0.15) |
8.70 (0.62) |
17.28 (0.53) |
Note: MM = medical management; CBI = combined behavioral intervention.
a
Assessments include assessments at baseline and those vitals/blood alcohol content readings taken at treatment sessions.
b
Total travel time includes travel to and from MM sessions, CBI sessions, and self-help program meetings.
c
Mean session times for “All Treatments” are conditional on treatment arms that provided the relevant service.
***
Mean patient times are statistically significantly different across all treatment arms at the 0.01 level by analysis of variance across treatment arms.